• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Dialysis: NxStage Medical reports record sales, hits new Wall Street low

Dialysis: NxStage Medical reports record sales, hits new Wall Street low

August 8, 2012 By MassDevice staff

NxStage Medical logo

NxStage Medical (NSDQ:NXTM) notched a new low watermark for the year, despite reporting a strong 2nd quarter with records sales.

NXTM shares briefly hit $13.20 today, the lowest they’ve been in the last 52 weeks. Shares regained few cents by the early afternoon to trade at $13.34, still down 16% on the day.

Shares dropped despite a record-breaking financial report, with revenues higher than the company’s ever scored for a single quarter.

The Fort Lauderdale, Fla.-based hemodialysis devices maker reported $59 million in sales during the 3 months ended June 30, a 9.8% spike from the same period last year.

"Our results in the 2nd quarter reflect solid and consistent progress. We achieved record revenues, a 300 bps improvement in gross margin, and advanced our robust product pipeline," CEO Jeff Burbank said in prepared remarks. "In sum, our growth strategy remains on track and we remain confident in our outlook for 2012."

NxStage also narrowed its losses during the quarter, reporting a net loss of $5.1 million, or 9¢ per share. That’s 8.8% lower than the $5.6 million, or 10¢ per share, lost during the same period last year.

NxStage has taken a hit in the last month following a proposed rule by the Centers for Medicare & Medicaid that failed to update reimbursement guidelines for home hemodialysis, dashing the company’s hopes of a more favorable physician payment environment – as well as some investors’ hopes of a near-term upside for NxStage Medical.

"Home and more frequent hemodialysis with the System One is great therapy that has been consistently reported to give patients access to a much richer and longer life. We continue to show that our therapy can benefit patients, providers and payors," Burbank said. "As a result, we continue to break down the barriers to adoption and deliver strong revenue growth consistent with our expectations."

NXTM shares have lost 27.5% since the proposal was published on July 3, when shares closed at $17.04.

NxStage North America president Joe Turk this week issued a public statement challenging CMS on its uninspiring policies for home hemodialysis. In a letter glibly titled “Really?”, Turk outlined his disappointment in the policy as proposed, offered a few quick fixes and urged stakeholders to submit suggestions on the rule during the open comment period – before the proposal becomes policy.

Filed Under: Dialysis, MassDevice Earnings Roundup, News Well, Wall Street Beat Tagged With: 2012, NxStage Medical Inc., Q2

More recent news

  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy